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Background: Chronic Obstructive Pulmonary Disease (COPD) is a worldwide public health 
concern. It is also a major source of disability that is often overlooked, depriving patients of 
effective treatments. This study describes the development and validation of a questionnaire 
specifically assessing COPD-related disability.
Methods: The DIsability RElated to COPD Tool (DIRECT) was developed according to refer-
ence methods, including literature review, patient and clinician interviews and test in a pilot study. 
A 12-item questionnaire was included for finalization and validation in an observational cross-
sectional study conducted by 60 French pulmonologists, who recruited 275 COPD patients of stage 
II, III and IV according to the GOLD classification. Rasch modeling was conducted and psychometric 
properties were assessed (internal consistency reliability; concurrent and clinical validity).
Results: The DIRECT score was built from the 10 items retained in the Rasch model. Their 
internal consistency reliability was excellent (Cronbach’s alpha = 0.95). The score was highly 
correlated with the Saint George’s Respiratory Questionnaire Activity score (r = 0.83) and the 
London Handicap Scale (r = −0.70), a generic disability measure. It was highly statistically 
significantly associated to four clinical parameters (P , 0.001): GOLD classification, BODE 
index, FEV1 and 6-minute walk distance.
Conclusion: DIRECT is a promising tool that could help enhance the management of COPD 
patients by integrating an evaluation of the COPD-related disability into daily practice.
Keywords: chronic obstructive pulmonary disease, daily medical practice, disability, disease 
management, questionnaires
Background
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease 
with some significant extrapulmonary effects that may contribute to its severity in 
individual patients. Its pulmonary component is characterized by airflow limitation 
that is not fully reversible. The airflow limitation is usually progressive and associated 
with an abnormal inflammatory response of the lung to noxious particles or gases, 
the main source of which is tobacco smoking. COPD is a leading cause of morbidity 
and mortality worldwide, is burdensome to patients, physicians, and society, partially 
because the pleomorphic nature of COPD manifestations goes far beyond the loss of 
pulmonary function associated with the disease.
For patients, the main burden of COPD is the impact it has on their daily lives.1 
Indeed, physical disability stemming from exercise-induced dyspnea, muscular decon-
ditioning, and other factors has a major impact on the self-perceived quality of life 
of the patients. Yet quality of life in COPD can be improved by several therapeutic International Journal of COPD 2011:6
Table 1 Concepts of interest identified during the development of DIRECT and corresponding items included in the questionnaire
General concepts Itemsa
Basic Activities of Daily Living (BADL) Does it ever bother you to talk and discuss things? (4-point Likert-type response scale 
ranging from “never” to “all of the time”)
Do you have trouble washing up or dressing? (4-point Likert-type response scale 
ranging from “never” to “all of the time”)
Instrumental Activities of Daily Living (IADL) Do you have trouble running small errands? (5-point Likert-type response scale ranging 
from “never” to “I am no longer able to do this” plus an additional response option “I am not 
the one who does the errands”)
Do you ever have trouble doing housework or do-it-yourself projects in the 
house? (5-point Likert-type response scale ranging from “never” to “I am no longer able 
to do this” plus an additional response option “I do not do housework or do-it-yourself 
projects”)
Advanced Activities of Daily Living (AADL) Do you ever have trouble going to places on foot? (5-point Likert-type response scale 
ranging from “never” to “I am no longer able to do this”)
Do you ever have trouble climbing stairs? (5-point Likert-type response scale ranging 
from “never” to “I am no longer able to do this”)
Impact on daily life Do your breathing problems limit what you like to do during your daily life? 
(4-point Likert-type response scale ranging from “never” to “all of the time”)
Do your breathing problems limit your relationships with others (in your daily life 
or at work)? (4-point Likert-type response scale ranging from “never” to “all of the time”)
Do you have to rely on others to do certain tasks because of your breathing 
problems? (4-point Likert-type response scale ranging from “never” to “all of the time”)
Do you have to rest during the day because of your breathing problems? (4-point 
Likert-type response scale ranging from “never” to “all of the time”)
Are you limited by your breathing problems in your sexual relationships? (5-point 
Likert-type response scale ranging from “never” to “I am no longer able to do this” plus an 
additional response option “I am not sexually active”)
Overall disability due to COPD Are your breathing problems a disability for you during your everyday life? 
(4-point Likert-type response scale ranging from “never” to “all of the time”)
Notes: aDIRECT was developed in French; these items are the output of the linguistic validation into US English. Copyright © 2011, Pfizer and Boehringer Ingelheim. 
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interventions, including the adequate use of bronchodilators2,3 
and pulmonary rehabilitation.4
Primary care physicians (PCPs) are increasingly recog-
nized as key to an optimal management of COPD.1,5 However, 
time is of the essence in routine medical practice and it is 
crucial for PCPs to have simple, practical decision-aid tools. 
Ideally, such tools should be responsive to educative and 
therapeutic interventions and therefore help practitioners 
and patients evaluate their effects.
Patient-reported instruments have been developed to 
investigate the impact of COPD on patients’ lives. However, 
these instruments were either designed in a clinical research 
framework6–9 or do not specifically assess disability.10–13
The objective of this study was to develop and validate a 
tool focusing specifically on COPD-related disability, appro-
priate for patients with a wide range of COPD severity.
Materials and methods
Development of the DIreCT 
questionnaire
The development of the DIsability RElated to COPD Tool 
(DIRECT) (August 2005–June 2008) included the following 
steps: 1) A literature review collected disability-related con-
cepts important to patients with COPD to develop the initial 
conceptual model of COPD-related disability; 2) Interviews 
with 3 PCPs eliciting general practitioners’ expectations and 
experiences regarding the diagnosis and management of COPD 
validated the relevance of the disability-related concepts identi-
fied; 3) Interviews with 10 COPD patients enhanced under-
standing of patients’ experiences of COPD and its impact on 
everyday life and collected patients’ own words as a basis for 
item generation; 4) The conceptual model of COPD-related 
disability describing the overall concepts and sub-concepts of 
interest was created, and questionnaire items were generated; 
5) Comprehension tests conducted with 5 COPD patients 
assessed the comprehension, relevance and acceptability of the 
tool’s instructions, questions and response choices and allowed 
modification of potential flaws in the questionnaire.
The result of this process is a self-administered ques-
tionnaire composed of twelve items assessing disability in 
COPD patients. The initial comprehension tests showed 
that less than 5 minutes are needed to complete it. Overall 
concepts, detailed concepts and response scales are presented 
in Table 1.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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DIRECT was then included in a small cross-sectional 
multicenter, observational study conducted in France to test it 
under real life conditions. This pilot study included 10 PCPs 
and 5 pulmonologists who recruited 40 COPD patients with 
a cumulative tobacco-smoking in excess of 10 pack-years, 
a post-bronchodilator Forced Expiratory Volume in 1 second 
(FEV1)/Forced Vital Capacity (FVC) ratio , 0.7 and a post-
bronchodilator FEV1 , 80% predicted without exacerbation 
for at least 1 month before the study. The completion rate was 
excellent since no missing data were observed in the question-
naire and the participating physicians’ feedback on the ques-
tionnaire was very good: all but one found the questionnaire 
useful and were considering using it in their daily practice.
Validation study
DIRECT was included for finalization and validation in an 
observational, multicenter, cross-sectional non-drug study 
conducted in 2009. One hundred French pulmonologists were 
asked to recruit 300 COPD patients with different stages of 
disease severity according to Global initiative for Obstructive 
Lung Disease (GOLD) classification 2008 (100 patients per 
stage II, III, and IV).14 The study was performed in accordance 
with good clinical practices and in compliance with local 
regulatory requirements. The appropriate national authorities 
and institutional review boards approved the protocol before 
study commencement. Each patient gave informed consent 
to participate. Eligible patients were those with a cumulative 
tobacco-smoking in excess of 10 pack-years, diagnosed with 
COPD with FEV1/FVC lower than 0.7, without exacerbation 
for at least 6 weeks and without any other chronic lung disease 
or serious and disabling disease, subjectively considered to 
be “major” by the physician and likely to compromise the 
patient’s participation in the study.
Investigators reported post-bronchodilator spirometric 
and blood gas measurements, 6-minute walk distance, 
COPD symptoms (sputum, cough), evaluation of physical 
and psychological disability and comorbidities listed in the 
Charlson comorbidity index (CCI).15 Patients completed 
3 patient-reported instruments in addition to the DIRECT 
questionnaire: Saint George’s Respiratory Questionnaire 
(SGRQ),16 London Handicap Scale (LHS)17 and Modified 
Medical Research Council (MMRC) Dyspnea scale.18 The 
SGRQ is frequently used to measure the impact of COPD 
and asthma on patient health status and provides three subdo-
main scores (Impact, Symptom and Activity) and one overall 
score. The LHS, a generic questionnaire evaluating patient’s 
self-perceived disability, allows the calculation of an overall 
handicap severity score ranging from 0 (maximum possible 
disadvantage) to 100 (no disadvantage). The MMRC Dyspnea 
scale consists of 5 statements about perceived breathlessness, 
characterizing 5 dyspnea grades. A French version of this 
scale has been specifically developed for this study, using a 
process including forward and backward translations.19 The 
body-mass index, airflow obstruction, dyspnea, and exercise 
capacity (BODE) index,20 a composite measure of COPD 
severity ranging from 0 to 10 that integrates respiratory, per-
ceptive and systemic aspects of COPD, was also computed.
Linguistic validation of DIreCT  
into Us english
After finalization, a US English version of DIRECT was 
obtained by a linguistic validation process according to pub-
lished standards21 including a conceptual analysis of the items, 
two independent forward translations from French to English, 
one backward translation, the review of the US English version 
by a clinician and its test with 5 COPD patients.
statistical analyses
The finalization of DIRECT included item selection and 
score definition. Distribution of item responses and quality 
of completion was observed. It assumed that all items mea-
sured the same underlying unidimensional concept (disability 
due to COPD). A principal component analysis (PCA) was 
applied in which the total variance was expected to be pre-
dominantly explained by the first factor and all items were 
expected to strongly load on this factor.
Partial-Credit Models (PCM),22 a generalization of Rasch 
modeling, were applied to the DIRECT items to select those 
producing a model with good measurement properties. 
Rasch modeling assumes that items and individuals can be 
located on a common continuum, called latent trait, which 
corresponds to the unidimensional concept that is measured 
by the items.23 In this case, the latent trait was COPD-related 
disability. The response of a patient to a given item is mod-
eled as a function of the respective locations of the item 
and the individual on the latent trait. Thus, items character-
izing worse health status are likely to be endorsed only by 
patients with severe disease whilst items corresponding to 
better health status are likely to be endorsed by patients with 
mild health problems. While the Rasch model involves only 
dichotomous items, PCM allow items with ordinal response 
scales to be analyzed by focusing on “item thresholds”: these 
are the values of the latent trait for which the most prob-
able response to an item changes (for example, the value of 
the latent trait for which the response “a little” to a given 
item becomes more probable than the response “not at all”). International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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An iterative approach was used to select items according to 
both the overall goodness-of-fit of the models by item-trait 
χ² and individual item fit evaluated by χ² values.24
The psychometric validation included assessment of 
concurrent and clinical validity and internal consistency 
reliability.25 Concurrent validity was measured by corre-
lating the DIRECT score with SGRQ scores, LHS overall 
handicap severity scores and MMRC dyspnea scale using 
Spearman correlation coefficients. The DIRECT score 
was expected to have high correlations with measures 
of functional limitations (SGRQ Activity score and LHS 
overall score). For clinical validity, the associations of 
the DIRECT score with GOLD classification, physician 
subjective assessment of physical and psychological dis-
ability, BODE index, FEV1, 6-minute walk distance and 
CCI were observed. The association with the DIRECT score 
was investigated using ANOVA for ordinal variables and 
linear regression for continuous variables. The reliability 
coefficient of the DIRECT score (ratio of variance in true 
score to the variance in observed score) was estimated using 
Cronbach’s coefficient alpha. Cronbach’s alpha assesses 
internal consistency reliability and is calculated from the 
correlations among items included in a score and the number 
of items in the score.
The DIRECT score was described according to GOLD 
stages using cumulative distribution curves.
All analyses were performed using SAS statistical soft-
ware version 9.2 (SAS Institute, Cary, NC, USA), except the 
Rasch modeling for which RUMM 2010 (RUMM Labora-
tory, Perth, Australia) was used. Results were considered 
statistically significant when the probability of a type I error 
was below 5%.
Results
Patient characteristics in the validation 
study
Of the 100 pulmonologists who accepted to participate in 
the study, 60 recruited a total of 275 patients. Two hundred 
and forty seven of the corresponding questionnaires had no 
missing data. The majority of patients (75.3%) were male. 
Mean age was 67 and 26.9% were active smokers (Table 2). 
COPD severity distribution was well balanced, with 36.0% 
in stage II, 33.5% in stage III and 30.5% in stage IV accord-
ing to GOLD classification 2008. Most patients coughed 
occasionally (46.9%) or daily (48.7%) and produced sputum 
(75.3%). Overall, 61.5% of the patients had experienced an 
exacerbation in the previous year. On average, patients had 
one comorbid condition in addition to COPD (mean CCI 
of 1.9). The number of comorbidities increased with COPD 
severity (mean CCI of 1.6, 1.8 and 2.2 in GOLD II, III and 
IV patients respectively).
Forty-one point five percent of the patients were treated 
by the combination of β2-agonists, glucocorticosteroids 
and long acting anticholinergics and 28% had home oxygen 
therapy (Table 3).
DIRECT finalization
All items had acceptable response distribution; no bimodal 
or skewed distribution was observed. The results of the 
finalization analyses are presented in Table 4. Most patients 
(89.8%) answered all questionnaire items. The percentage 
of missing data per item ranged from 4.7% to 8.0%, with 
item 11, concerning sexual activities, showing the highest 
percentage of missing data. The first factor of the principal 
component analysis explained 58.4% of the total variance of 
the 12 items of the questionnaire, supporting the unidimen-
sionality hypothesis.
Item selection and scoring algorithm
Items 11 (“Impact on sex life”) and 12 (“Handicap due to 
COPD”) were eliminated from the calculation of the score 
because of their poor fit to the partial credit model. After 
reduction to a 10-item model, the overall fit of the model 
was very good (item-trait interaction χ² = 27.452; P = 0.60). 
Only item 1 (“Trouble talking”) showed a significant χ² 
value, indicating poor fit; however, because the overall fit 
was acceptable and this item potentially has great clinical 
value, it was retained. The distribution of item thresholds 
and patients on the latent trait (COPD-related disability) are 
presented in Figure 1. The DIRECT score was constituted 
by the unweighted sum of the responses to the 10 items 
retained in the partial credit model, yielding a score ranging 
between 0 and 34, with higher values indicating higher levels 
of disability.
DIreCT validation
Concurrent validity
The DIRECT score showed high correlation with the SGRQ 
Activity score (0.83) (Table 5). The correlations between the 
DIRECT score and the SGRQ Impact and Total scores were 
also very high (0.83 and 0.87 respectively). The DIRECT 
score was also highly correlated with the LHS overall 
handicap score and MMRC dyspnea scale (−0.70 and 0.73 
respectively) and its correlation with the SGRQ Symptom 
score was lower than the correlations above, but was still 
fairly high (0.61).International Journal of COPD 2011:6
Table 2 Patient demographics and clinical characteristics in the overall population and according to gOLD stage
Overall population 
(n = 275)
GOLD stage II 
(n = 99)
GOLD stage III 
(n = 92)
GOLD stage IV 
(n = 84)
Demographics and smoking
Age – mean (sD) 67.1 (10.7) 66.7 (11.3) 66.9 (10.8) 67.7 (9.8)
gender – male (%) 75.3 79.8 71.7 73.8
smoking status – active smoker (%) 26.9 31.3 21.7 27.4
number of pack-years – mean (sD) 44.7 (19.9) 42.1 (16.4) 42.3 (20.0) 50.3 (22.3)
Spirometric measurement
FeV1
 n 275 99 92 84
  Mean % predicted (sD) 44.7 (14.8) 61.1 (7.9) 40.7 (5.7) 29.8 (7.4)
FVC
 n 272 98 91 83
  Mean % predicted (sD) 65.9 (17.9) 78.0 (13.2) 64.0 (14.6) 53.6 (17.0)
sVC
 n 241 88 80 73
  Mean % predicted (sD) 69.5 (18.8) 80.1 (14.8) 67.8 (17.4) 58.5 (17.6)
IC
 n 162 54 52 56
  Mean % predicted (sD) 65.9 (24.7) 78.1 (24.4) 61.0 (22.9) 58.7 (22.6)
rV
 n 259 93 86 80
  Mean % predicted (sD) 174.8 (67.6) 155.4 (48.4) 173.7 (69.8) 198.4 (77.1)
FrC
 n 165 63 51 51
  Mean % predicted (sD) 138.0 (44.1) 125.5 (34.6) 137.7 (39.9) 153.7 (53.4)
TLC
 n 266 96 88 82
  Mean % predicted (sD) 110.5 (28.5) 106.4 (23.7) 109.9 (28.7) 116.0 (32.5)
Arterial blood gases
PaO2
 n 228 77 75 76
  Mean mmhg (sD) 68.1 (12.0) 74.9 (10.2) 70.7 (9.2) 58.6 (10.0)
PaCO2
 n 227 76 75 76
  Mean mmhg (sD) 40.4 (5.2) 38.6 (4.2) 39.9 (4.7) 42.6 (5.7)
Symptoms and comorbidities
6-minute walk distance
 n 275 99 92 84
  Mean % of predicted value (sD) 69.3 (28.0) 82.0 (23.0) 73.5 (28.1) 49.5 (22.3)
Chronic cough – % 
  never 4.0 4.0 3.3 4.8
  Occasionally 46.9 55.6 50.0 33.3
  Daily 48.7 40.4 45.7 61.9
sputum production – % 75.3 78.8 68.5 78.6
exacerbation in the past 12 months – % 61.5 49.5 59.8 77.4
CCI
 n 275 99 92 84
  Mean (sD) 1.9 (1.1) 1.6 (0.9) 1.8 (1.1) 2.2 (1.2)
BODe index
 n 250 91 84 75
  Mean score (sD) 4.1 (2.5) 2.0 (1.5) 4.3 (1.8) 6.4 (1.7)
Abbreviations:  FeV1,  post-bronchodilator  Forced  expiratory  volume  in  one  second;  post-bronchodilator  FVC,  Forced  Vital  Capacity;  sVC,  slow  Vital  Capacity;   
IC, Inspiratory Capacity; rV, residual Volume; FrC, Functional residual Capacity; TLC, Total Lung Capacity.
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Clinical validity
The difference in the mean DIRECT score was statisti-
cally significant in groups defined according to GOLD 
stages (P , 0.001), physician subjective assessment of 
  physical disability (P , 0.001), and physician assessment 
of psychological disability (P , 0.001) (Table 6). Sig-
nificant relationships were observed in univariate linear 
regressions linking the DIRECT score and the BODE 
index (P , 0.001; R² = 0.47), post-bronchodilator 
FEV1 (P , 0.001; R2  = 0.25), 6-minute walk International Journal of COPD 2011:6
Table 3 Management of COPD in the overall population and according to gOLD stage
Overall population 
(n = 275)
GOLD stage II 
(n = 99)
GOLD stage III 
(n = 92)
GOLD stage IV 
(n = 84)
Drug treatment – %
  short acting β2-agonist or anticholinergics 2.9 6.1 1.1 1.2
  short acting and long acting β2-agonist or  
  anticholinergics – no glucocorticosteroids
9.5 16.2 6.5 4.8
 β 2-agonists + glucocorticosteroids 17.1 12.1 20.7 19.0
 β 2-agonists + glucocorticosteroids + long  
  acting anticholinergics
41.5 26.3 51.1 48.8
  Othera 26.9 33.3 20.7 26.2
home oxygen therapy – % 28.0 15.2 19.6 52.4
Pulmonary rehabilitation – % 22.2 12.1 25.0 31.0
regular respiratory exercise – % 28.0 19.2 27.2 39.3
Note: aOther includes other combinations of treatments as well as other treatment such as methylxanthine.
submit your manuscript | www.dovepress.com
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distance (P , 0.001; R² = 0.21) and CCI (P , 0.001; 
R² = 0.05).
Internal consistency reliability
Cronbach’s alpha coefficient calculated for the 10-item 
score was very high at 0.947, indicating excellent internal 
consistency reliability.
Description of DIreCT score
The cumulative distributions of the DIRECT score according 
to GOLD stage are given in Figure 2.
The following mean (SD) DIRECT scores were also 
calculated: 12.1 (7.7) in smokers, 15.3 (8.3) in ex-smokers 
(P , 0.01); 16.2 (8.0) in patients who had an exacerbation 
in the previous 12 months, 11.6 (7.6) in those who had not 
(P , 0.001); 21.0 (6.7) in patients with home oxygen   therapy, 
11.9 (7.3) in patients without (P , 0.001); 17.7 (8.2) in 
patients who participated in rehabilitation   programs, 13.4 
(7.9) in patients who did not (P , 0.001).
Discussion
At the end of a development and validation process adhering 
to reference methods,26,27 the 10-item, self-administered, 
“Disability RElated to COPD Tool” (DIRECT) appears to 
have very good measurement properties. Item generation 
encompassed both the clinical judgment of practitioners 
and opinions of patients in terms of content and wording. 
It was well accepted by patients and physicians during 
Table 4 Finalization of the DIRECT questionnaire: Quality of completion and principal component analysis loadings on the first factor 
of the items and final partial-credit model results
DIRECT item content Percentage  
of missing 
data 
(n = 275)
PCA first  
factor 
loading  
(n = 247)
Final (10-item) partial-credit model results (n = 247)
Item goodness of fit Item thresholdsb 
χ² P-valuea 1st 2nd 3rd 4th
  1. Trouble talking 5.5 0.70 10.20 ,0.001 −2.6 0.4 2.2 –
  2.   Trouble washing or  
getting dressed
4.7 0.77 3.05 0.37 −1.8 0.4 1.3 –
  3. Trouble doing shopping 5.1 0.65 1.99 0.56 −2.9 −0.2 1.0 2.1
  4. Trouble doing housework 5.5 0.60 1.49 0.68 −3.6 −0.2 1.4 2.4
  5. Trouble walking 4.7 0.87 3.81 0.26 −4.5 −0.8 0.7 4.7
  6. Trouble climbing stairs 4.7 0.78 4.65 0.17 −4.6 −0.9 0.5 4.9
  7. Impact on every day life 5.1 0.87 2.80 0.41 −3.3 0.5 2.8 –
  8. Impact on social life 5.1 0.81 1.04 0.79 −2.4 0.2 2.2 –
  9. rely upon others 5.5 0.83 0.45 0.93 −3.0 0.3 2.7 –
10.   Taking rest during  
the day
5.1 0.82 1.22 0.74 −2.9 −0.1 3.0 –
11. Impact on sex life 8.0 0.48 – – – – – –
12. handicap due to COPD 4.7 0.89 – – – – – –
Notes: aSignificant P-value means rejection of the hypothesis of good item fit (indicates poor fit); bItem thresholds are the value of the latent trait corresponding to the 
boundaries between adjacent response categories. For example, the first threshold indicates the value of the latent trait below which the most probable response is the first 
response option and above which the most probable response is the second response option.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 rasch analysis – Distribution of patients and item thresholds on the latent trait (n = 247). 
This figure allows patients and item thresholds (ie, value corresponding to the boundaries between adjacent response categories) to be represented on the same scale, the 
latent trait (X-axis): the distribution of patients is plotted in the top part of the figure; the distribution of thresholds is plotted in the bottom part. In this instance, the latent 
trait (X-axis) represents the disability. The range of disability levels of included patients was wide but the items of the questionnaire covered this wide range of disability 
levels fairly well.
Table 5 Concurrent validity of the DIRECT score: Spearman correlation coefficients between patient-reported outcomes scores 
(n = 247)
DIRECT  
score
SGRQ symptom  
score
SGRQ activity  
score
SGRQ impact  
score
SGRQ total  
score
LHS overall handicap   
severity score
sgrQ symptom score 0.61
sgrQ activity score 0.83 0.56
sgrQ impact score 0.83 0.72 0.78
sgrQ total score 0.87 0.78 0.87 0.97
Lhs overall handicap  
severity score
−0.70 −0.45 −0.70 −0.65 −0.70
MMrC dyspnea scale 0.73 0.48 0.70 0.70 0.72 −0.67
Abbreviations: LHS, London Handicap Scale; MMRC, Modified Medical Research Council; SGRQ, St Georges Respiratory Questionnaire.
the test phase and the pilot study, as well as during the 
validation study. All possible score values were observed 
in the study population, and the score did not exhibit floor 
or ceiling effects; this indicates adequate coverage of the 
measured concept, namely the extent of COPD-related 
disability.
In line with the approach underpinning the international 
classification of functioning, disability and health (ICF) 
promoted by the World Health Organization (WHO),28 the 
questionnaire focuses on disability and functioning as an 
interaction between health condition (ie, COPD and respira-
tory problems, in this specific case) and contextual factors. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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It covers activities of daily living potentially impacted by 
COPD to various degrees (dressing/washing oneself; shop-
ping; cleaning/doing handwork at home; walking; climbing 
stairs; talking) and more global aspects, but still related to 
disability, like self-perceived general impact on everyday life, 
impact on social life, and impact on interactions with others. 
Though the items about sex life and overall handicap due to 
COPD were removed from the score because they weakened 
the overall fit of the partial-credit models, they were kept 
in the questionnaire, at least provisionally. The “impact on 
sex life” item was retained in order to prompt discussions 
between physicians and patients on this sensitive topic. 
Ninety-two percent of the patients did answer this question, 
which suggest that this does represent a relevant issue. Among 
the patients who declared themselves sexually active, about 
80% mentioned suffering from respiratory-related limitations 
in this area of their life. This is consistent with COPD having 
a negative impact on sexual activity, a notion that is intuitive 
but has not been the object of extensive attention to date.29 The 
item about the overall handicap due to breathing difficulties 
was retained as it may be a good candidate for an extremely 
rapid assessment summarizing all the aspects covered by the 
questionnaire, without having to calculate any score. Indeed, 
as it is positioned at the end of the questionnaire, from a cog-
nitive perspective, it can be assumed that the response of the 
patient will be reflecting the various aspects addressed in the 
questionnaire. The relevance of keeping these two items in the 
questionnaire should be tested further in future studies.
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Figure 2 Cumulative distribution curves of the DIreCT score according to gOLD stage (n = 247).
Note: Cumulative distribution curves display the percentage of patients (Y-axis) having at least a given score (X-axis). half of gOLD stage II patients had DIreCT scores 
below 7 (point A), half of gOLD stage III patients had DIreCT scores lower than 14 (point B) and half of gOLD stage IV patients had DIreCT scores lower than 19   
(point C). This graph also shows the percentage of patients in each group who had a DIreCT score lower than 17, the mid-point of the scale: this was 85% in gOLD stage II 
(point D), 65% in gOLD stage III (point e), and only about 30% in gOLD stage IV.
Table 6 Clinical validity of DIreCT score (n = 247)
N DIRECT score P-valuea
Mean SD
COPD severity according to GOLD classification
gOLD stage II 93 9.9 6.8 ,0.001
gOLD stage III 84 14.7 7.5
gOLD stage IV 70 20.0 7.2
Physician assessment of physical handicap
not at all 3 3.7 3.5 ,0.001
A little 36 5.7 5.2
Moderately 94 12.0 6.6
A lot 91 18.3 6.7
enormously 21 24.1 5.5
Physician assessment of psychological handicap
not at all 24 6.9 5.8 ,0.001
A little 91 12.0 7.8
Moderately 72 15.1 7.6
A lot 49 19.7 6.0
enormously 9 23.1 9.3
Note: aAnOVA P-value for between-group comparisons.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The 10-item score had an excellent fit to a partial-credit 
model, supporting its interval scaling properties. It also 
exhibited very high internal consistency reliability. The 
reliability of a measurement instrument closely depends 
on measurement error. If measurement error is too great, it 
becomes unreasonable to use a questionnaire for individual 
decisions. Conversely, reliability coefficient values as high 
as 0.95, like those reached by DIRECT in this study, allow 
decisions to be made at the individual level.30 In addition, 
DIRECT was closely correlated with variables indicative of 
the severity of COPD and its ability to discriminate between 
patient groups was excellent. Thus, it is reasonable to expect 
DIRECT to be useful at the individual level.
The DIRECT score was closely correlated to well- 
established patient-reported outcomes instruments. 
Excellent correlations were found not only with respiratory-
specific questionnaires such as the SGRQ and the MMRC 
scale, but also with the results of a generic measure of 
handicap, the LHS. This indicates that despite the brevity 
of the questionnaire, the score is a valid measure of COPD-
related disability. The DIRECT score was also significantly 
associated with comorbidities as measured by the CCI, even 
though the strength of this association was marginal (only 
5% of the DIRECT score variance was explained by the 
CCI). This indicates that while DIRECT mainly captures 
COPD-related disability, it does not completely disregard 
the potential impact on daily living of the frequent comor-
bid conditions.
In interpreting the results of this observational study, 
it is important to consider the nature of the population 
under scrutiny. Although the overall population was well 
balanced regarding GOLD stages, it might be slightly 
different than “standard” COPD populations. Indeed, rest-
ing hyperinflation seemed highly prevalent, with a mean 
functional residual capacity (FRC) of 125% predicted and 
a mean inspiratory capacity (IC) of 65% predicted in the 
GOLD stage II patients. This might be considered surpris-
ing, as GOLD stage II patients often have normal FRC 
and IC/TLS ratios, see for example Albuquerque et al.31 
Yet hyperinflation is a major determinant of COPD-related 
impairment in activities of daily living.32 Possibly in line 
with this, the proportion of patients receiving triple therapy 
with long-acting beta-agonists, inhaled corticosteroids, 
and a long acting anticholinergic was high (41.5% of the 
overall population). More than 50% of GOLD stage IV 
patients received home oxygen, which might also indicate 
a selection bias toward a severe population. However, 
even though these specific features of the study population 
could alter the estimation of the level of disability due to 
COPD, they do not have a major impact on the primary 
objective of the study, ie, the assessment of DIRECT’s 
psychometric properties.
Other patient-completed questionnaires that could be 
used in daily medical practice to help with COPD patient 
management have been proposed in recent years: the COPD 
Assessment test (CAT),11 the clinical COPD questionnaire 
(CCQ),12,13 or the visual simplified respiratory questionnaire 
(VSRQ).10 These instruments cover various aspects of the 
health status of COPD patients (symptoms, energy, sleep, 
etc.) and can help physicians get a better global picture. 
But, as illustrated on Figure 3, focusing on disability can be 
instrumental to certain therapeutic decisions, like the pre-
scription of long-acting bronchodilators or the initiation of 
a rehabilitation program. In addition, monitoring the impact 
of therapeutic interventions on disability makes a lot of sense 
Diagnosis
Symptoms
Health status
Disability
Comorbidities
Optimized
treatment
Specific tests
CAT
VSRQ
CCQ
MRC dyspnea scale
Spirometry
Available tools
DIRECT
Exercise Testing
Figure  3  schematic  representation  of  COPD  patient  management  with  tools 
available to physicians.
Abbreviations:  MrC,  Medical  research  Council;  CAT,  COPD  Assessment 
Test;  CCQ,  Clinical  COPD  Questionnaire;  VSRQ,  Visual  Simplified  Respiratory 
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from a clinical perspective. For these reasons and because 
the impact of COPD on activities of daily living is critical to 
the patients,1 a specific measure of COPD-related disability 
should usefully complement the currently available patient-
reported evaluation tools.
With this in mind, DIRECT was devised to help PCPs 
recognize COPD-related disability, for them to integrate 
this dimension of the disease and take it into account in their 
management strategy. The whole development process was 
customized to this objective. Intended for use in a primary care 
setting, DIRECT was purposely short and easily administered, 
with a score that can be calculated by hand without any kind 
of weighting. Of note, DIRECT is not a COPD diagnosis 
tool. It is intended to become one of the instruments that 
are available to holistically describe a COPD patient (like, 
for example, exercise testing or nutritional assessment) and 
support therapeutic decisions by providing a standardized 
assessment. It could also, if proven responsive to interven-
tions, be used to monitor the efficacy of these therapeutic 
decisions. Several options can be envisioned for the use of 
DIRECT in routine practice.
Firstly, DIRECT could be used to support patient-clini-
cian communication about COPD-related disability. Indeed, 
the goals and expectations of the patients and their physicians 
do not always coincide during a consultation.33 Discussing 
the principles of disease management and agreeing upon 
them optimizes the chances of success.34 Any tool likely 
to facilitate this exchange is therefore worth consideration. 
In this respect, DIRECT can be useful because it provides 
additional information on a specific, concrete aspect of COPD 
that is highly relevant to patients, even though it is seldom 
brought forward spontaneously.
Secondly, DIRECT could be used by PCPs as a decision 
aid when disability should be considered (eg, initiation of 
long-acting bronchodilators, or pulmonary rehabilitation). 
DIRECT has been shown to be a valid and reliable measure of 
COPD-related disability but interpretation guides should be 
given to support COPD management decisions. The available 
results (namely the PCM results, the cumulative distribu-
tion curve, or the distribution of DIRECT scores in various 
subgroups) can provide raw interpretation rules. Indeed, it 
could be hypothesized that a DIRECT score greater than 
10 indicates a noticeable disability and that a DIRECT score 
above 20 indicates high levels of disability. Nonetheless, 
further research is needed to refine these reference values 
and optimize decision rules from DIRECT.
Thirdly, DIRECT could help monitor the efficacy of 
therapeutic strategies by assessing their impact on disability. 
This will imply studies of its responsiveness to interventions 
aimed at improving COPD-related disability and known to 
improve quality of life at population (eg, the pulmonary 
rehabilitation-related improvement in the SGRQ)35 and 
individual level.
Conclusion
To conclude, we submit that DIRECT is a promising instru-
ment for the identification of COPD-related disability in 
routine practice. Some work remains to be done before 
DIRECT is used for daily management of COPD patients. 
Some evidence on its responsiveness to interventions and 
practical decision rules to make its score more operational 
would be of great value in this purpose. Additional language 
versions of the questionnaire, cautiously taking into account 
the possible interference of cultural issues, would also allow 
its use in international settings. Nonetheless, we are confident 
that its focused nature will foster physician/patient discus-
sions and expose more patients to interventions that improve 
their capacity to perform daily activities.
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